Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Siemens AG    SIE   DE0007236101

Delayed Quote. Delayed  - 07/29 05:35:05 pm
97.12 EUR   +0.42%
07/29 SIEMENS : Balancing Renewables in the New Energy Landscape
07/28 SIEMENS : delivers first Saudi made gas turbines
07/27 SIEMENS : secures follow-up onshore wind project in Australia
News SummaryMost relevantAll newsSector news 

Siemens AG : WSJ BLOG/Health : Siemens Sees Resurgence in Diagnostics as a Cost Cutter

share with twitter share with LinkedIn share with facebook
share via e-mail
04/13/2012 | 07:02pm CEST

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)

By Shirley S. Wang

The Health Blog caught up at TEDMED with Gregory Sorensen, chief executive of Siemens Healthcare in North America, to talk about the changing health-care field and what it means for diagnostics, an area in which Siemens is a player.

"We're beginning to see resurgence in diagnostics as a way to save costs, " Sorensen, formerly a radiology professor at Harvard Medical School, told the Health Blog.

A missed diagnosis is a big cost driver in health care because it wastes time and money on ineffective therapy, he said, pointing to an example of studies in Alzheimer's showing that upon autopsy, some 15%-20% of patients examined had a different ailment than believed and would have been treated differently when they were alive.

Of course, there's been an outcry about the unnecessary use of medical tests and Sorensen acknowledges there has been overuse in the past. Reductions in Medicare reimbursement rates have curbed overuse, he says, though not everyone agrees on that, as the Health Blog reported last week. The important thing now, Sorensen says, is to make sure people are getting the right diagnostic tests, rather than reduce the absolute number of them.

He recalled being a doctor in training in the late 1980s, when his professors taught him that, because of the risks associated with appendicitis, doctors should be conservative whenever a patient reported pain in the lower right quadrant of the abdomen. A good surgeon, therefore, would do exploratory surgery on five patients for every one that actually had appendicitis. Sorensen himself had his appendix -- which turned out to be healthy -- removed during this era.

Now patients get scanned if they report such pain, resulting in many fewer unnecessary surgeries, said Sorensen.

Siemens recognizes how important it is to demonstrate effectiveness in today's health-care business, and that payers want to see results, says Sorensen. As for the shift to reimbursement for value, "that train has left the station."

 -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com. 

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SIEMENS AG
07/29 SIEMENS : Balancing Renewables in the New Energy Landscape
07/29 SIEMENS : Product Lifecycle Management Software Assigned Patent
07/28 SIEMENS : delivers first Saudi made gas turbines
07/27 SIEMENS : secures follow-up onshore wind project in Australia
07/27 SIEMENS : Flexible Combined Cycle Power Generation
07/27 SIEMENS : to Supply Compressor Trains for TAP Project
07/26 SIEMENS : delivers first Saudi made gas turbines
07/26 SIEMENS : secures follow-up onshore wind project in Australia
07/26 SIEMENS : ships its first “Made in KSA” gas turbine
07/26 SIEMENS : New Solution Partners for Siemens Large Drives
More news
Sector news : Industrial Conglomerates
07/29DJTalend Nudges Dormant Tech IPO Market
07/29DJSafran in Talks Over Future of ID & Security Business
07/28 Dow Chemical says cost savings will likely exceed FY target
07/28DJDOW CHEMICAL : Profit Tops Views
07/28DJDOW CHEMICAL : Profit Tops Views
More sector news : Industrial Conglomerates
News from SeekingAlpha
07/18 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q2 2016 Update
07/14 Catch The Wind
07/11 FT : Siemens backs away from Brexit warnings
07/11 Climate Change, A Generational Investment Opportunity
07/07 EXA : Expensive Solo... Cheap In A Buyout
Financials (€)
Sales 2016 79 590 M
EBIT 2016 7 566 M
Net income 2016 5 324 M
Debt 2016 16 456 M
Yield 2016 3,74%
P/E ratio 2016 14,85
P/E ratio 2017 13,45
EV / Sales 2016 1,24x
EV / Sales 2017 1,18x
Capitalization 82 552 M
More Financials
Duration : Period :
Siemens AG Technical Analysis Chart | SIE | DE0007236101 | 4-Traders
Full-screen chart
Technical analysis trends SIEMENS AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 101 €
Spread / Average Target 3,7%
Consensus details
EPS Revisions
More Estimates Revisions
Josef Kaeser Chairman-Management Board
Gerhard Cromme Chairman-Supervisory Board
Ralf Peter Thomas Chief Financial Officer
Siegfried Russwurm Chief Technology Officer
Michael Diekmann Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SIEMENS AG7.52%92 252
3M CO18.40%107 801
E I DU PONT DE NEMOURS..3.86%60 477
More Results